Compares two diabetes drug types for heart and kidney protection in type 2 diabetes
Compares two diabetes drug types in adults with type 2 diabetes and heart disease.
Key facts
- Who runs it
- Brigham and Women's Hospital
- Where
- Ann Arbor, Baltimore, Boston, Charleston, Charlotte, Chicago, Columbia, Danville, Duluth, Durham, Fairway, Hinsdale, Huntsville, Iowa City, Johns Creek, Katy, Los Angeles, Manassas, McKinney, Miami, Milwaukee, Minneapolis, Nashville, New York, Omaha, Orangeburg, Pawtucket, Pembroke Pines, Philadelphia, Portland, Scottsdale, Suwanee, Wooster, and Worcester, United StatesSee the 36 sites
- Trial code
- Registry title
- PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 6,000 people, planned
- Started
- 26 Sept 2022
- Expected to end
- 1 Mar 2029
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- SGLT2 inhibitor
- GLP-1 receptor agonist
- Record updated
- 13 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with type 2 diabetes who already have atherosclerotic heart or blood vessel disease, or are at high risk of it. They will be randomly given one of two diabetes medicines.
- Age
- 40 to 80 years. People with existing vessel disease: 40 to 80. People without it but at high risk: 60 to 80.
- Sex
- All sexes can join.
- Disease stage
- Type 2 diabetes with HbA1c of 6% (42 mmol/mol) or higher in the past 12 months. Most people (at least 70%) must have established atherosclerotic disease: heart, brain-vessel or leg-artery disease. Up to 30% may be without it, if aged 60 to 80 with one more high-risk feature: active smoking, HbA1c of 8% (64 mmol/mol) or higher, or kidney function (eGFR) of 45 to 59.
- Earlier treatment
- People already taking an SGLT2 inhibitor or a GLP-1 receptor agonist must be willing to stop it and be assigned to one of the two. They must also be willing to avoid starting the other class during the trial.
- Biomarker or test result
- HbA1c of 6% (42 mmol/mol) or higher in the past 12 months. For the group without vessel disease, one high-risk feature is needed, such as HbA1c of 8% (64 mmol/mol) or higher or eGFR 45 to 59.
Main reasons for not taking part
- Diabetes of another cause, such as type 1 diabetes
- History of diabetic ketoacidosis, pancreatitis, or active diabetic foot ulcer
- Heart failure as main reason for hospital stay in the past year, or known ejection fraction below 40%
- eGFR below 45 or urine albumin-to-creatinine ratio above 200 mg/g
- History of solid organ or bone marrow transplant, or allergy to the study drugs
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- Type 2 diabetes based on clinical diagnosis
- HbA1c ≥6% measured within 12 months prior to screening
- Secondary prevention cohort (at least 70% of cohort):; Age 40 to 80 years; Evidence of established atherosclerotic cardiovascular disease (ASCVD), as defined by one or more of the following; Coronary heart disease defined by at least one of the following: prior myocardial infarction, prior coronary percutaneous coronary intervention, ≥50% stenosis of a coronary artery documented by invasive or non-invasive imaging (including CT coronary angiography), positive stress test, or coronary artery calcium score >400 Agatston units; Cerebrovascular disease defined by at least one of the following: prior ischemic stroke, prior carotid revascularization procedure, carotid stenosis ≥ 50% documented by X-ray angiography, MR angiography, CT angiography, or Doppler ultrasound; Symptomatic peripheral artery disease defined by at least one of the following: leg symptoms with an ABI ≤ 0.9, leg symptoms with imaging evidence of a stenosis ≥50% in a peripheral artery documented by X-ray angiography, MR angiography, CT angiography, or Doppler ultrasound, or prior amputation for atherosclerotic disease
- Primary prevention cohort (capped at 30% of cohort):; Age 60-80 years and at least 1 additional high-risk feature:; Cardiovascular risk factors/high-risk features:; Active smoking (combustible tobacco or marijuana); HbA1c ≥ 8% measured within 12 months prior to screening. The most recent value available at the time of screening will be used for screening and to determine eligibility; Stage 3a CKD, eGFR 45-59 ml/min/1.73m2 measured within 12 months prior to screening. The most recent value available at screening will be used for screening and to determine eligibility
- Willingness to be randomly assigned to medication class (SGLT2i or GLP-1 RA or both) and fill prescription through personal pharmacy benefit while having other medications adjusted for safety
- Willingness to avoid starting a therapy in the alternative treatment group (e.g., if randomized to GLP-1 RA, avoid starting an SGLT2i) unless strongly recommended by the participant's usual care provider
- If taking one of the study medication classes, willingness to stop SGLT2i or GLP-1 RA and be randomly assigned to one of the two medication classes
- Willingness to consent to data collection using the electronic health record and sign a medical release to obtain future medical records from other health care facilities
Who cannot take part
- Known inability to afford study medication through current insurance coverage
- Active treatment for cancer, planned treatment for cancer, or recent active cancer with likelihood of recurrence or progression, which, in the opinion of the site investigator, has a likelihood of recurrence that would interfere with study therapy prior to 2028; Treated cancer with no evidence of disease, no evidence of disease progression, and no planned change in therapy is allowed. Examples of allowable cancers include:; Breast cancer stable after active treatment, managed with long-term anti-estrogen therapy; Prostate cancer being observed; Stage 0 or 1 tumors status post resection or other definitive treatment; Other similarly stable cancer comorbidities
- Known or suspected diabetes of other cause (type 1 diabetes, pancreatogenic diabetes, monogenic diabetes, etc.)
- Any background diabetes medication regimen will be allowed in this pragmatic trial with the following proviso:; o Participants taking basal-bolus, prandial, or multiple daily injection insulin (MDI) regimens (e.g., short-acting in combination with long-acting insulin, called MDI regimens) are eligible only if the research staff attests that there has been communication with the usual diabetes care provider and that the provider has agreed to manage insulin adjustment with initiation of study medications. If such agreement has not been obtained, participants taking MDI regimens are excluded
- History of diabetic ketoacidosis
- Active diabetic foot ulcer
- History of pancreatitis
- Heart failure as a primary reason for hospitalization within the past year
- History of solid organ or bone marrow transplant
- Allergy to SGLT2 inhibitor or GLP-1 receptor agonist
- Known left ventricular ejection fraction <40%
- Known urinary albumin-to-creatinine ratio >200 mg/g at screening
- Estimated glomerular filtration rate (eGFR) less than 45 ml/min/1.73m2 measured within 12 months prior to screening. The most recent value available at screening will be used for screening and to determine eligibility
- If a woman of child-bearing potential, the patient or partner is unwilling to use birth control
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 80 years old?
Where in United States
- University of MichiganAnn Arbor, United StatesContact: Brittany WilliamsTaking people
- Johns Hopkins School of MedicineBaltimore, United StatesContact: Jamie HymanTaking people
- MedStar Health Research Institute - Good Samaritan HospitalBaltimore, United StatesContact: Sariat IbrahimTaking people
- MedStar Union Memorial HospitalBaltimore, United StatesContact: Flossine Brown, BS, CRCTaking people
- Brigham and Women's HospitalBoston, United StatesContact: Krista ScartozziTaking people
- Medical University of South CarolinaCharleston, United StatesContact: Audra WiserTaking people
- Atrium Health Family Medicine Research DepartmentCharlotte, United StatesContact: Andrea PriceTaking people
- University of Illinois ChicagoChicago, United StatesContact: Julia LawTaking people
- University of Missouri - ColumbiaColumbia, United StatesContact: Katelyn SmithTaking people
- Geisinger Medical CenterDanville, United StatesContact: Megan OliveriTaking people
- Essentia HealthDuluth, United StatesContact: Leah TatelovichTaking people
- Duke University HospitalDurham, United StatesContact: Chad HarrellTaking people
- University of Kansas Medical CenterFairway, United StatesContact: Erica Lower, CCRPTaking people
- Rush University Medical CenterHinsdale, United StatesContact: Sharon GlinskiTaking people
- Longwood Research LLCHuntsville, United StatesContact: Jeff DunlapTaking people
- University of IowaIowa City, United StatesContact: Laura SeegmillerTaking people
- NSC Research, IncJohns Creek, United StatesContact: Charlotte MallTaking people
- Premier Internal Medicine Associates of HoustonKaty, United StatesContact: Nausheen MujeebTaking people
- Eastside Clinical Research AssociatesLos Angeles, United StatesContact: Mayra VazquezTaking people
- Kidney and Hypertension Specialists, PLLCManassas, United StatesContact: Hanan Ebjad, MD, MHSATaking people
- North Dallas Research AssociatesMcKinney, United StatesContact: Samina AhsanullahTaking people
- Kendall South Medical Center, IncMiami, United StatesContact: Denise MorenoTaking people
- Medical College of WisconsinMilwaukee, United StatesContact: Kailie RothTaking people
- University of MinnesotaMinneapolis, United StatesContact: Sarah ManserTaking people
- Vanderbilt University Medical CenterNashville, United StatesContact: Alesia PruittTaking people
- Naomi Berrie Diabetes Center at New York Presbyterian-Columbia UniversityNew York, United StatesContact: Angel SuzanaTaking people
- University of Nebraska Medical CenterOmaha, United StatesContact: Khadieja M AbuzahoTaking people
- South Carolina Clinical Research LLCOrangeburg, United StatesContact: Payton PadgettTaking people
- Family Care Center at Kent HospitalPawtucket, United StatesContact: Angela LarkinTaking people
- South Florida Research Solutions LLCPembroke Pines, United StatesContact: Smelda FerrinTaking people
- Temple University Lewis Katz School of MedicinePhiladelphia, United StatesContact: Jackson WeilerTaking people
- Oregon Health Science UniversityPortland, United StatesContact: Aly CarlsonTaking people
- HonorHealth Research & Innovation InstituteScottsdale, United StatesContact: Nadia MadiasTaking people
- Herman Clinical ResearchSuwanee, United StatesContact: Morgan EcholsTaking people
- Wooster Heart GroupWooster, United StatesContact: John RoofTaking people
- UMass Chan Medical SchoolWorcester, United StatesContact: Xhenifer MeleTaking people
About the trial
What the trial wants to find out
PRECIDENTD is a randomized, open label, pragmatic clinical trial designed to compare rates of the total number of cardiovascular, kidney, and death events among two alternative treatments for patients with type 2 diabetes (T2D) and either established atherosclerotic cardiovascular disease (ASCVD) or at high risk for ASCVD. To accomplish this objective, we will randomly assign 6,000 patients with established T2D and ASCVD or high-risk for ASCVD in a 1:1 allocation to sodium-glucose cotransporter-2 inhibitor (SGLT2i) or glucagon-like peptide-1 receptor agonists (GLP-1RA). Participants will be followed for the occurrence of the trial primary endpoint of the total (first and recurrent) number of episodes of myocardial infarction (MI), stroke, arterial revascularization, hospitalization for heart failure, development of end-stage kidney disease, kidney transplantation, and mortality, counting all events from randomization until end of study.
The 2 groups in the trial
- Sodium-glucose cotransporter-2 inhibitor (SGLT2i)Existing treatment, for comparison
Therapy with an SGLT2i with proven cardiovascular benefit. This means either canagliflozin, dapagliflozin, or empagliflozin
Treatment: SGLT2 inhibitor
- Glucagon-like peptide-1 receptor agonist (GLP-1 RA)Existing treatment, for comparison
Therapy with a GLP-1 RA with proven cardiovascular benefit. This means either dulaglutide, liraglutide, or semaglutide.
Treatment: GLP-1 receptor agonist
Results explained
A paper that names this trial, explained in plain words.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- PRECIDENTD: PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes
- Plain-language title
- Compares two diabetes drug types for heart and kidney protection in type 2 diabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT05390892, who can take part
- Publications
- Dual versus monotherapy with SGLT2 inhibitor and GLP-1 receptor agonist: PRECIDENTD pragmatic randomized trial.American heart journal, 2026
- Record updated
- 13 April 2026